[{"id":"754b3b22-626c-418f-a2c1-e76dc14ce5ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT04509596","created_at":"2021-01-18T21:37:06.335Z","updated_at":"2024-07-02T16:35:37.391Z","phase":"Phase 1","brief_title":"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer","source_id_and_acronym":"NCT04509596","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • capecitabine • DZD1516"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/21/2020","start_date":" 09/21/2020","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-09-12"}]